CORAL GABLES, FL, February 21, 2013 — Catalyst Pharmaceutical Partners, Inc. (Nasdaq:
CPRX), a specialty pharmaceutical company focused on the development and commercialization
of novel prescription drugs targeting rare (orphan) neurological diseases and disorders, is pleased
to announce the launch of its newly designed website. The site can be accessed at
“As we continue to make progress and further our plans for the transformation of Catalyst to a
company developing novel prescription drugs to treat rare neurological diseases, we felt that it
was important to upgrade and revamp our website”, said Patrick J. McEnany, Chief Executive
Officer of Catalyst.
About the Website
The site provides an information platform for patients, physicians and investors in an easy to
The aim of the site is to allow visitors to gain a comprehensive understanding of the Company’s
drug candidates. Patients and other interested parties can learn about Catalyst’s drug candidates,
related clinical trials and the science behind them. Website visitors will have an ability to follow
the progress of the drug candidates and Company’s development in the News and Events
sections. Current and potential investors will have the ability to download the latest information
on the Company in the Investors section.
In keeping with Catalyst’s mission to provide treatment for rare neurological diseases through
collaboration with patients, physicians, scientists and other constituencies, the new website also
offers multiple ways of contacting the Company. All the inputs will be carefully reviewed and
will serve as a basis for further development of the website. The ultimate goal is to eventually
expand the website into a forum for patients, physicians and other stakeholders to share
information, ideas and recommendations.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the
development and commercialization of prescription drugs targeting rare (orphan) neurological
diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile
spasms, and Tourette’s syndrome. Catalyst's lead candidate, FirdapseTM for the treatment of
LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is
also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by
Catalyst) to treat infantile spasms, and epilepsy, as well as other neurological conditions
associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's
disorder, and movement disorders associated with the treatment of Parkinson's Disease.
This press release contains forward-looking statements. Forward-looking statements involve
known and unknown risks and uncertainties, which may cause the Company’s actual results in
future periods to differ materially from forecasted results. A number of factors, including
whether any of the Company's product candidates will ever be approved for commercialization
and those factors described in the Company’s filings with the U.S. Securities and Exchange
Commission (SEC), could adversely affect the Company. Copies of the Company’s filings with
the SEC are available from the SEC, may be found on the Company’s website or may be
obtained upon request from the Company. The Company does not undertake any obligation to
update the information contained herein, which speaks only as of this date.